UPDATED: Astellas pauses Audentes' gene therapy program again after 'abnormal' liver tests in yet another setback
Audentes’ troubled the gene therapy program for a rare and devastating muscle wasting disease isn’t yet out of the woods.
The Astellas subsidiary has once again halted a trial for its X-linked myotubular myopathy candidate, the Japanese Pharma announced, after a serious adverse event emerged in which researchers observed “abnormal liver function tests” within the first month of dosing. The hold is voluntary for now, but Astellas left open the possibility of receiving an official FDA notice.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.